An exploratory open-label study of rosacea patients to study the efficacy and tolerability of
erenumab in the prophylactic treatment of persistent redness and flushing attributed to
rosacea. Approximately 30 subjects will be included in the study and receive erenumab 140 mg
for three months. The study will begin June 2020 and is expected to last nine months.
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!
Enable functional cookies in order to access shared annotations.
The passcode will expire in None.
Loading...
No annotations made yet
Add a private note
Select a piece of text from the left.
Add notes visible only to you.
Send it to people through a passcode protected link.
Send Notes
Loading...
Publish Annotation
Are you sure you want to publish the annotation?
Delete AnnotationNote
Are you sure you want to delete the annotationnote?